Physician profile
Matthew Dashnaw
NPI 1720220940
$2,794.97
in general payments reported to CMS, 2019-2025
15 companies · $28.95 in 2025
The $28.95 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $177 · 2021: $323 · 2022: $240 · 2023: $346 · 2024: $1,268 · 2025: $28.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,156 · Food and Beverage: $468 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,155.63 |
| Food and Beverage | $467.94 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,262.66 | 2023-2024 | Proclaim |
| Nevro Corp. | $1,049.10 | 2019-2023 | Senza |
| Mml US, INC. | $143.89 | 2023 | Reactiv8 |
| Novocure INC. | $61.94 | 2019 | |
| Depuy Synthes Sales INC. | $49.46 | 2023-2024 | Matrixneuro, Teligen |
| Aesculap, INC. | $37.86 | 2020 | |
| Azurity Pharmaceuticals, INC. | $32.94 | 2023 | Gliadel |
| Globus Medical, INC. | $28.95 | 2025 | Senza |
| Medtronic USA, INC. | $28.62 | 2020 | |
| Intrinsic Therapeutics | $23.27 | 2022 | |
| Csl Behring | $20.00 | 2024 | Kcentra |
| Arbor Pharmaceuticals, INC. | $15.64 | 2019 | |
| Theragen, INC. | $13.77 | 2021 | |
| Bioventus LLC | $13.76 | 2022 | |
| Medtronic, INC. | $13.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Dashnaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.